Amgen PREPAREs Aranesp For Yet Another Hit
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III interim results evaluating the anemia drug in cancer setting show more deaths, higher rate of tumor progression.
You may also be interested in...
European Regulators Approve Labeling Update For Amgen’s Aranesp
Revised European ESA prescribing information consistent with proposal released last fall.
European Regulators Approve Labeling Update For Amgen’s Aranesp
Revised European ESA prescribing information consistent with proposal released last fall.
Amgen Says 2007 Profits Will Top October Projections
California biotech cites cost-cutting measures as reason for upgraded earnings per share guidance of $4.30.